Company profile
Clearmind Medicine Inc., a clinical stage pharmaceutical company, develops novel psychedelic medicines to treat under-served health problems. The company develops treatments for alcohol use disorders, binge drinking, and eating disorders, as well as weight loss, obesity, and metabolic syndrome, anxiety disorders, post-traumatic stress disorder, depression, and treatment resistant depression. It develops MEAI compound for the treatment of alcohol use disorder, obesity, and metabolic disorders, as
- CEO
- Dr. Adi Zuloff-Shani Ph.D.
- Headquarters
- Vancouver, BC, Canada
- Employees
- 0
- IPO date
- Aug 16, 2021
- Sector
- Healthcare
- Industry
- Biotechnology